Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851133 · ClinicalTrials.gov registry record
Florida Pancreas Collaborative Next Generation Biobank
A clinical trial of Pancreatic Cancer and Cancer Cachexia, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 500
- Enrollment target
- 14
- Study locations
NCT03851133: Active study of Pancreatic Cancer and Cancer Cachexia, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT03851133 is a study of Pancreatic Cancer and Cancer Cachexia that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 500 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 14 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03851133, a study of Pancreatic Cancer and Cancer Cachexia, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this study is to partner with individuals known or suspected to have pancreatic cancer to build a biobank dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. A biobank is a resource that involves collection, processing and storage of blood, other bodily fluids, and tissue.
Primary Outcome
Cases will be evaluated for precachexia using the following guidelines: Anorexia with \<5% weight loss over past 6 months along with metabolic changes that together indicate precachexia.
Conditions Studied
Interventions
- OTHER Data Collection
- OTHER Blood Sample Collection
- OTHER Tumor Sample collection
Study Locations (14)
Florida
- Lee Memorial Hospital Regional Cancer Center - Fort Myers
- University of Florida - Gainesville - Gainesville
- Palmetto General Hospital - Hialeah
- University of Florida - Jacksonville - Jacksonville
- Lakeland Regional Health - Lakeland
- Sylvester Comprehensive Cancer Center & Jackson Memorial Hospital - Miami
- Mount Sinai Medical Center - Miami Beach
- Advent Health - Orlando - Orlando
- University of Florida - Orlando - Orlando
- Sarasota Memorial Hospital - Sarasota
- St Anthony's Baycare/Bay Surgical Specialists - St. Petersburg
- Tallahassee Memorial Healthcare - Tallahassee
- University of South Florida/Tampa General Hospital - Tampa
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2026-06-11 |
What the registry record for NCT03851133 still lists
NCT03851133 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Data Collection is the first listed.
NCT03851133 lists 14 locations in 1 state (Florida).
Frequently Asked Questions
What is clinical trial NCT03851133 about?
NCT03851133 is a clinical study titled "Florida Pancreas Collaborative Next Generation Biobank". The goal of this study is to partner with individuals known or suspected to have pancreatic cancer to build a biobank dedicated to minimizing disparities and personalizing care for individuals affected by pancreatic cancer. A biobank is a resource that involves collection, processing and storage of ...
What is the current status of trial NCT03851133?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2019-03-04. Estimated completion is 2026-06-11.
What conditions does trial NCT03851133 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Cancer Cachexia.
What interventions are being tested in trial NCT03851133?
The interventions under investigation include: Data Collection (OTHER), Blood Sample Collection (OTHER), Tumor Sample collection (OTHER).
Who is sponsoring clinical trial NCT03851133?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03851133 being conducted?
This trial has 14 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03851133's enrollment target sits among peer trials
500 30th of 278 higher than 247 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI